2018
A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections
Chattopadhyay A, Aguilar PV, Bopp NE, Yarovinsky TO, Weaver SC, Rose JK. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections. Vaccine 2018, 36: 3894-3900. PMID: 29807712, DOI: 10.1016/j.vaccine.2018.05.095.Peer-Reviewed Original ResearchConceptsChikungunya virusZika virusA129 miceVesicular stomatitis virusChimeric vesicular stomatitis virusZika virus infectionWild-type miceSingle-dose vaccineRecombinant virus vaccineCo-circulating virusesLicensed vaccineSingle vaccinationZIKV infectionAntibody responsePandemic proportionsVirus vaccineVirus infectionAnimal modelsExperimental vaccinesVaccineMiceInfectionInvasive mosquito vectorsVSV glycoproteinVirus
2013
Identification of a Region in the Stalk Domain of the Nipah Virus Receptor Binding Protein That Is Critical for Fusion Activation
Talekar A, DeVito I, Salah Z, Palmer SG, Chattopadhyay A, Rose JK, Xu R, Wilson IA, Moscona A, Porotto M. Identification of a Region in the Stalk Domain of the Nipah Virus Receptor Binding Protein That Is Critical for Fusion Activation. Journal Of Virology 2013, 87: 10980-10996. PMID: 23903846, PMCID: PMC3807285, DOI: 10.1128/jvi.01646-13.Peer-Reviewed Original ResearchConceptsNewcastle disease virusReceptor binding proteinParamyxovirus fusion activationStalk domainBinding proteinAvian Newcastle disease virusHost cellsViral envelope glycoproteinsFusion activationNiV FEnvelope glycoproteinReceptor binding regionsTarget cellsNipah virusSialic acid moietiesDisease virusFusion signalChimeric proteinMembrane fusionReceptorsGlobular domainFusion proteinAttachment proteinCellular membranesActivation
2010
Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach
Chattopadhyay A, Rose JK. Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach. Journal Of Virology 2010, 85: 2004-2011. PMID: 21177820, PMCID: PMC3067786, DOI: 10.1128/jvi.01852-10.Peer-Reviewed Original Research
2008
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection
Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 2008, 26: 6329-6337. PMID: 18832004, PMCID: PMC2628553, DOI: 10.1016/j.vaccine.2008.09.031.Peer-Reviewed Original ResearchConceptsTime of challengeVesicular stomatitis virusVaccine protectionAnti-LcrV antibodySingle-dose protectionDepletion of CD4Recombinant vesicular stomatitis virusYersinia pestis challengeCellular immunityAntibody titersSingle doseIgG1 isotypePlague vaccineLcrV proteinOptimal protectionPlague challengeCD4Stomatitis virusCellsCD8IgG2aVaccineMiceDoseTiters